

NOVO NORDISK A S  
Form 6-K  
February 19, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

February 18, 2019

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

\_\_\_\_\_

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

**Novo Nordisk A/S – Share repurchase programme**

**Bagsværd, Denmark, 18 February 2019** – On 1 February 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation No 1052/2016 of 8 March 2016, also referred to as the Safe Harbour Regulation. This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.

Under the programme initiated 1 February 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 1 February 2019 to 1 May 2019.

Since the announcement as of 11 February 2019, the following transactions have been made under the programme:

|  | <b>Number of<br/>B shares</b> | <b>Average<br/>purchase price</b> | <b>Transaction<br/>value, DKK</b> |
|--|-------------------------------|-----------------------------------|-----------------------------------|
| <b>Accumulated, last announcement</b>  | <b>839,000</b>                |                                   | <b>267,154,215</b>                |
| 11 February 2019                       | 140,000                       | 321.03                            | 44,944,365                        |
| 12 February 2019                       | 140,000                       | 323.33                            | 45,266,181                        |
| 13 February 2019                       | 140,000                       | 324.90                            | 45,485,564                        |
| 14 February 2019                       | 138,000                       | 326.99                            | 45,125,004                        |
| 15 February 2019                       | 138,000                       | 328.54                            | 45,338,368                        |
| <b>Accumulated under the programme</b> | <b>1,535,000</b>              |                                   | <b>493,313,697</b>                |

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](http://novonordisk.com).



With the transactions stated above, Novo Nordisk owns a total of 58,855,766 B shares of DKK 0.20, corresponding to 2.4% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,450,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 15 February 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 1,535,000 B shares at an average share price of DKK 321.38 per B share equal to a transaction value of DKK 493,313,697.

*Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube.*

## **Further information**

### *Media:*

|                      |                 |                      |
|----------------------|-----------------|----------------------|
| Anne Margrethe Hauge | +45 4442 3450   | amhg@novonordisk.com |
| Ken Inchausti (US)   | +1 609 240 9429 | kiau@novonordisk.com |

### *Investors:*

|                         |               |                      |
|-------------------------|---------------|----------------------|
| Peter Hugrefte Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Anders Mikkelsen        | +45 3079 4461 | armk@novonordisk.com |
| Valdemar Borum Svarrer  | +45 3079 0301 | jvls@novonordisk.com |
| Kristoffer Due Berg     | +45 3079 2849 | krdb@novonordisk.com |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |

**Novo Nordisk A/S**  
Investor Relations

Novo Allé  
2880 Bagsværd  
Denmark

Telephone:  
+45 4444 8888

Internet:  
[www.novonordisk.com](http://www.novonordisk.com)  
CVR no:  
24 25 67 90

Company announcement No 10 / 2019

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: February 19, 2019

Lars Fruergaard Jørgensen

Chief Executive Officer